News
Displaying 11–20 of 493
-
Research News
Strengthening research in retinal disease with record-breaking $19.8 million investment in innovative projects targeting vision loss worldwide.
-
Atsena’s LCA1 Gene Therapy Licensed by Nippon Shinyaku for Markets in US and Japan
Research NewsThe companies are planning a Phase 3 clinical trial for the promising gene therapy.
-
BlueRock’s Photoreceptor Cell Therapy to Move into Clinical Trial
Research NewsThe Foundation funded Dr. David Gamm for development of the induced pluripotent stem cell approach to be used in the trial.
-
Kiora Receives Authorization for Phase 2 Clinical Trial of its Photoswitch for Advanced RP
Research NewsThe 36-participant trial will take place at multiple sites in Australia.
-
The RD Fund Announces Ocuphire Pharma’s Acquisition of Opus Genetics
In the PressThe resulting company will operate under the name Opus Genetics and the Nasdaq ticker symbol (IRD).
-
Opus Genetics, Ocuphire Merger to Boost Advancement of Several IRD Gene Therapies
Research NewsMerger will provide additional capital for gene therapy development.
-
MicroRNA Breakthroughs: Paving the Way for Vision Restoration
Research NewsResearchers funded by the Foundation Fighting Blindness are developing microRNA-based therapies for inherited retinal diseases, building on recent Nobel Prize-winning discoveries.
-
Safety Clinical Trial Launched for Usher Syndrome 3 Drug
Research NewsResearchers hope the molecule will slow the vision and hearing loss associated with USH3.
-
Vision: A Memoir of Blindness and Justice — A New York Times Editor’s Pick
Foundation News“Tatel’s humility and tenacity shine. The result is a stirring reflection on an extraordinary life,” Publishers Weekly
-
Foundation News
Social media campaign to encourage personal story sharing to spread awareness about blinding diseases and empower involvement with the Foundation Fighting Blindness.
